UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
IRS Employer Identification No.) |
(Address of principal executive offices)
Registrant’s telephone
number, including area code: (
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||
| |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
On December 4, 2023, Dr. Robert Foster, the Company's CEO, resigned from the Company as CEO for personal reasons, effective immediately. In connection therewith, on December 4, 2023, Dr. Foster resigned from the Board of Directors of the Company.
On December 4, 2023, the Board of Directors appointed John Cavan, the Company’s Chief Financial Officer, as interim Chief Executive Officer.
On December 4, 2023, Dr. Peter Wijngaard resigned from the Board of Directors of the Company. Dr. Wijngaard was a member of the Company’s Audit Committee.
| Item 8.01 | Other Events. |
On December 6, 2023, the Company issued a press release announcing (i) that its Board of Directors has approved a strategic restructuring plan, (ii) the resignation of Dr. Foster as the Company's CEO for personal reasons and (iii) the appointment of John Cavan as interim Chief Executive Officer. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Hepion Pharmaceuticals, Inc. Press Release |
| 104 | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the inline XBRL document |
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 7, 2023
| HEPION PHARMACEUTICALS, INC. | ||
| By: | /s/ John Cavan | |
| John Cavan | ||
| Interim Chief Executive Officer and Chief Financial Officer | ||
-3-